Abstract
Purpose: The 2017 publication of the ASCENDE-RT Trial demonstrated the efficacy of trimodality treatment in high-risk prostate cancer patients. Despite superior biochemical progression-free survival (b-PFS), the treatment was associated with higher GI and GU toxicities compared to external beam alone. We analyzed patients treated in a similar manner in Kelowna in the years following accrual to ASCENDE-RT to see if outcomes and toxicity rates remain comparable outside a clinical trial selected population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
